Active Recombinant Human VTCN1 protein, Fc-tagged, Biotinylated

• Cat.No.: VTCN1-051H
• Product Overview: Biotinylated Recombinant Human VTCN1(Phe29-Ala258) protein, fused to Fc tag at the C-terminus, was expressed in HEK293 cells .

Specification

• Description: VTCN1 is a 50­80 kDa glycosylated member of the B7 family of immunomodulatory proteins (1, 2). Mature human B7­H4 consists of a 235 amino acid (aa) extracellular domain (ECD) with one Ig­like V­set domain and one Ig­like C2­set domain, a 21 aa transmembrane segment, and a 2 aa cytoplasmic tail (3­5). Within the ECD, human B7­H4 shares 90% aa sequence identity with mouse and rat B7­H4. It shares 22% ­ 28% aa sequence identity with human B7­1, B7­2, B7­H1, B7­H2, B7­H3, and PD­L2. Alternate splicing of human B7­H4 generates an additional isoform that lacks the first Ig­like domain. B7­H4 is expressed on the surface of activated lymphocytes, macrophages, monocytes, dendritic cells, epithelial cells, and bone marrow­derived mesenchymal stem cells (4­8). Its binding to activated T cells dampens T cell responses and induces cell cycle arrest in the T cell (3­5). Reverse signaling can induce either cell cycle arrest or apoptosis in the B7­H4 expressing cell (9, 10). B7­H4 is up­regulated in several carcinomas in correlation with tumor progression and metastasis (2, 7, 11, 12). A soluble form of B7­H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status (13­15). Soluble B7­H4 functions as a decoy molecule that blocks the inhibitory influence of B7­H4 on immune activation (15). Despite evidence for the involvement of B7­H4 in immune regulation, mice deficient in its expression do not show significant immune deficiencies, suggesting compensation by other molecules in vivo (16).
• Source: HEK293 cells
• Species: Human
• Tag: Fc
• Predicted N Terminal: Phe29
• Form: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Bio-activity: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 0.1-0.5 μg/Ml.
• Molecular Mass: 81-94 kDa and 170 - 195 kDa, reducing conditions
• Protein length: Phe29-Ala258
• Endotoxin: <0.10 EU per 1 μg of the protein by the LAL method.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Applications: Bioactivity
• Storage: 12 months from date of receipt, ≤ -20 °C as supplied.1 month, 2 to 8 °C under sterile conditions after reconstitution.3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Reconstitution: Reconstitute at 100 μg/mL in PBS.

Gene Information

• Gene Name: VTCN1 V-set domain containing T cell activation inhibitor 1 [ Homo sapiens ]
• Official Symbol: VTCN1
• Synonyms: VTCN1; V-set domain containing T cell activation inhibitor 1; V-set domain-containing T-cell activation inhibitor 1; B7 family member; H4; B7 superfamily member 1; B7 H4; B7H4; B7S1; B7X; FLJ22418; B7 family member, H4; T cell costimulatory molecule B7x; T-cell costimulatory molecule B7x; immune costimulatory protein B7-H4; B7-H4; B7h.5; VCTN1; PRO1291; RP11-229A19.4
• Gene ID: 79679
• mRNA Refseq: NM_001253849
• Protein Refseq: NP_001240778
• MIM: 608162
• UniProt ID: Q7Z7D3